Correction: Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination.

[This corrects the article DOI: 10.1371/journal.pone.

Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination.

Background: Initiated in 2016, End Hep C SF is a comprehensive initiative to eliminate hepatitis C (HCV) infection in San Francisco. The introduction of direct-acting antivirals to treat and cure HCV provides an opportunity for elimination. To properly measure progress, an estimate of baseline HCV prevalence, and of the number of people in various subpopulations with active HCV infection, is required to target and measure the impact of interventions.

Knowledge of hepatitis B risk factors and prevention practices among individuals chronically infected with hepatitis B in San Francisco, California.

Asian/Pacific Islanders (A/PIs) in the United States are disproportionately affected by the hepatitis B virus (HBV), which can cause a lifelong liver infection that may result in cirrhosis, liver failure, liver cancer, or death. Although previous studies have measured knowledge of hepatitis B transmission and prevention practices in A/PI communities, we present results from the first population-based study of this type, which specifically focuses on A/PIs who are chronically infected with HBV. Through telephone interviews, we assessed the HBV risk factor knowledge and prevention practices of a population-based, random sample of persons with chronic HBV who were reported to the San Francisco Department of Public Health between October 2007 and July 2009.